Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women’s health, oncology, and other therapeutic categories. In addition, it offers pharmaceutical products in the areas of urology, gastroenterology, and dermatology therapeutic categories. The company produces medicines in various formulations, including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids, and semi-solids. It sells its products in Ireland and internationally. Actavis plc was founded in 1983 and is based in Little Island, Ireland. The company has development and manufacturing facilities in Europe, the United States, and Asia.
actavis plc (ACT:New York)
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
|Abbott Laboratories||$47.01 USD||-0.08|
|AbbVie Inc||$60.27 USD||+0.65|
|Allergan Inc/United States||$235.68 USD||+0.82|
|Eli Lilly & Co||$70.65 USD||+0.28|
|Takeda Pharmaceutical Co Ltd||¥6,516 JPY||+126.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ACTAVIS PLC, please visit www.actavis.ie. Company data is provided by Capital IQ. Please use this form to report any data issues.